Cite
Retraction Note: The BET inhibitor I-BET762 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine.
MLA
Xie, Fang, et al. “Retraction Note: The BET Inhibitor I-BET762 Inhibits Pancreatic Ductal Adenocarcinoma Cell Proliferation and Enhances the Therapeutic Effect of Gemcitabine.” Scientific Reports, vol. 13, no. 1, Nov. 2023, pp. 1–2. EBSCOhost, https://doi.org/10.1038/s41598-023-48298-9.
APA
Xie, F., Huang, M., Lin, X., Liu, C., Liu, Z., Meng, F., Wang, C., & Huang, Q. (2023). Retraction Note: The BET inhibitor I-BET762 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine. Scientific Reports, 13(1), 1–2. https://doi.org/10.1038/s41598-023-48298-9
Chicago
Xie, Fang, Mei Huang, Xiansheng Lin, Chenhai Liu, Zhen Liu, Futao Meng, Chao Wang, and Qiang Huang. 2023. “Retraction Note: The BET Inhibitor I-BET762 Inhibits Pancreatic Ductal Adenocarcinoma Cell Proliferation and Enhances the Therapeutic Effect of Gemcitabine.” Scientific Reports 13 (1): 1–2. doi:10.1038/s41598-023-48298-9.